Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.
Zinzani PL, Pellegrini C, Merla E, Ballerini F, Fabbri A, Guarini A, Pavone V, Quintini G, Puccini B, Vigliotti ML, Stefoni V, Derenzini E, Broccoli A, Gandolfi L, Quirini F, Casadei B, Argnani L, Baccarani M. Zinzani PL, et al. Among authors: quirini f. Hematol Oncol. 2013 Dec;31(4):179-82. doi: 10.1002/hon.2036. Epub 2012 Oct 29. Hematol Oncol. 2013. PMID: 23108928
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.
Zinzani PL, Pellegrini C, Gandolfi L, Stefoni V, Quirini F, Derenzini E, Broccoli A, Argnani L, Pileri S, Baccarani M. Zinzani PL, et al. Among authors: quirini f. Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):462-6. doi: 10.1016/j.clml.2011.02.001. Epub 2011 May 4. Clin Lymphoma Myeloma Leuk. 2011. PMID: 21859554 Clinical Trial.
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years.
Casadei B, Pellegrini C, Pulsoni A, Annechini G, De Renzo A, Stefoni V, Broccoli A, Gandolfi L, Quirini F, Tonialini L, Morigi A, Argnani L, Zinzani PL. Casadei B, et al. Among authors: quirini f. Cancer Med. 2016 Jun;5(6):1093-7. doi: 10.1002/cam4.684. Epub 2016 Mar 14. Cancer Med. 2016. PMID: 26990782 Free PMC article.
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma.
Zinzani PL, Tani M, Pulsoni A, De Renzo A, Stefoni V, Broccoli A, Montini GC, Fina M, Pellegrini C, Gandolfi L, Cavalieri E, Torelli F, Scopinaro F, Argnani L, Quirini F, Derenzini E, Rossi M, Pileri S, Fanti S, Baccarani M. Zinzani PL, et al. Among authors: quirini f. Ann Oncol. 2012 Feb;23(2):415-20. doi: 10.1093/annonc/mdr145. Epub 2011 May 2. Ann Oncol. 2012. PMID: 21536660 Free article. Clinical Trial.
Hairy cell leukemia: evaluation of the long-term outcome in 121 patients.
Zinzani PL, Pellegrini C, Stefoni V, Derenzini E, Gandolfi L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccarani M. Zinzani PL, et al. Among authors: quirini f. Cancer. 2010 Oct 15;116(20):4788-92. doi: 10.1002/cncr.25243. Cancer. 2010. PMID: 20597132 Free article.
13 results